- Home
- AEON vs MYNZ Comparison
AEON vs MYNZ Comparison
Compare AEON & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEON | MYNZ |
|---|---|---|
| Founded | N/A | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 8.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AEON | MYNZ |
|---|---|---|
| Price | $1.04 | $1.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.20 | ★ $14.00 |
| AVG Volume (30 Days) | 157.1K | ★ 188.9K |
| Earning Date | 11-14-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.38 | $0.92 |
| 52 Week High | $47.68 | $8.20 |
Technical Indicators
Market Signals| Indicator | AEON | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 62.96 | 46.86 |
| Support Level | $0.72 | $1.00 |
| Resistance Level | $1.13 | $1.29 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 81.22 | 42.37 |
Price Performance
Historical ComparisonAbout AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.